DNA damage response inhibitors enhance tumour treating fields (TTFields) potency in glioma stem-like cells.

ABSTRACT:

Background

High-grade gliomas are primary brain cancers with unacceptably low and persistent survival rates of 10-16 months for WHO grade 4 gliomas over the last 40 years, despite surgical resection and DNA-damaging chemo-radiotherapy. More recently, tumour-treating fields therapy (TTFields) has demonstrated modest survival benefit and been clinically approved in several countries. TTFields is thought to mediate anti-cancer activity by primarily disrupting mitosis. However, recent data suggest that TTFields may also attenuate DNA damage repair and replication fork dynamics, providing a potential platform for therapeutic combinations incorporating standard-of-care treatments and targeted DNA damage response inhibitors (DDRi).

Methods

We have used patient-derived, typically re

SUBMITTER: Vanderlinden A 

PROVIDER: S-EPMC10667536 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature